Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM

Bulletin Express05-27

Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan Meeting Room, Wanda Vista Beijing.

Key agenda items are split into ordinary and special resolutions:

1. Ordinary resolutions • Approval of the Board Report, Supervisory Committee Report, audited consolidated financial statements and full Annual Report for the year ended 31 December 2025. • Endorsement of the 2025 profit distribution plan. • Review of the independent non-executive directors’ 2025 work report. • Confirmation of the directors’ remuneration (allowance) plan. • Re-appointment of the external auditor for the 2026 financial year.

2. Special resolutions • Granting a general mandate to the Board to repurchase H shares. • Granting a general mandate to the Board to issue H shares. • Abolishment of the Supervisory Committee and corresponding amendments to the Articles of Association.

Shareholders may appoint the chairman of the meeting or other designated proxies to vote on their behalf. The completed proxy form, together with any power of attorney, must be lodged with Computershare Hong Kong Investor Services Limited to be valid for the meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123331571?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123331571","market":"hk","top_or_hot":-1,"title":"Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan Meeting Room, Wanda Vista Beijing.</p>\n<p>Key agenda items are split into ordinary and special resolutions:</p>\n<p>1. Ordinary resolutions  \n• Approval of the Board Report, Supervisory Committee Report, audited consolidated financial statements and full Annual Report for the year ended 31 December 2025.  \n• Endorsement of the 2025 profit distribution plan.  \n• Review of the independent non-executive directors’ 2025 work report.  \n• Confirmation of the directors’ remuneration (allowance) plan.  \n• Re-appointment of the external auditor for the 2026 financial year.</p>\n<p>2. Special resolutions  \n• Granting a general mandate to the Board to repurchase H shares.  \n• Granting a general mandate to the Board to issue H shares.  \n• Abolishment of the Supervisory Committee and corresponding amendments to the Articles of Association.</p>\n<p>Shareholders may appoint the chairman of the meeting or other designated proxies to vote on their behalf. The completed proxy form, together with any power of attorney, must be lodged with Computershare Hong Kong Investor Services Limited to be valid for the meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-27 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan Meeting Room, Wanda Vista Beijing.</p>\n<p>Key agenda items are split into ordinary and special resolutions:</p>\n<p>1. Ordinary resolutions  \n• Approval of the Board Report, Supervisory Committee Report, audited consolidated financial statements and full Annual Report for the year ended 31 December 2025.  \n• Endorsement of the 2025 profit distribution plan.  \n• Review of the independent non-executive directors’ 2025 work report.  \n• Confirmation of the directors’ remuneration (allowance) plan.  \n• Re-appointment of the external auditor for the 2026 financial year.</p>\n<p>2. Special resolutions  \n• Granting a general mandate to the Board to repurchase H shares.  \n• Granting a general mandate to the Board to issue H shares.  \n• Abolishment of the Supervisory Committee and corresponding amendments to the Articles of Association.</p>\n<p>Shareholders may appoint the chairman of the meeting or other designated proxies to vote on their behalf. The completed proxy form, together with any power of attorney, must be lodged with Computershare Hong Kong Investor Services Limited to be valid for the meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1123331571","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123331571","pubTimestamp":1779872659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物将在2026年6月18日股东周年大会上寻求股东批准2025年报告、利润分配和董事会授权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan Meeting Room, Wanda Vista Beijing.\nKey agenda items are split into ordinary and special resolutions:\n1. Ordinary resolutions  \n• Approval of the Board Report, Supervisory Committee Report, audited consolidated financial statements and full Annual Report for the year ended 31 December 2025.  \n• Endorsement of the 2025 profit distribution plan.  \n• Review of the independent non-executive directors’ 2025 work report.  \n• Confirmation of the directors’ remuneration (allowance) plan.  \n• Re-appointment of the external auditor for the 2026 financial year.\n2. Special resolutions  \n• Granting a general mandate to the Board to repurchase H shares.  \n• Granting a general mandate to the Board to issue H shares.  \n• Abolishment of the Supervisory Committee and corresponding amendments to the Articles of Association.\nShareholders may appoint the chairman of the meeting or other designated proxies to vote on their behalf. The completed proxy form, together with any power of attorney, must be lodged with Computershare Hong Kong Investor Services Limited to be valid for the meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123331571","isCrawlerRequest":true}